Direct encapsulation of tobramycin sulfate for gastrointestinal lumen exposure is performed on an intermittent-motion dosator capsule filler after a two-stage tumble blending sequence. The API is first passed through a 600 μm stainless-steel sieve and pre-blended with microcrystalline cellulose at a 1:3 ratio in a double-cone blender operating at 25 rpm for 10 minutes with a fill volume of 50% of working capacity. The pre-blend is then passed through a 425 μm screen with pregelatinized starch and colloidal silicon dioxide and mixed for an additional 15 minutes. Final blend samples are taken at 10 geometrically distinct positions and assayed by a stability-indicating liquid chromatographic procedure using the current USP Tobramycin Sulfate Reference Standard. The lot is accepted when blend relative standard deviation is ≤ 5.0% and mean assay is 95.0%–105.0% of label claim; batch failure in the upper sampling position has been observed when fill volume exceeds 70%, and the corrective action is reduction of batch size rather than extension of blend time, because prolonged tumbling can induce fines segregation and content non-uniformity.

During encapsulation, fill weight is monitored by in-line checkweighing at intervals not exceeding 15 minutes; individual capsule mass is held within ± 5.0% of target and the shell is size 0 hard gelatin or hypromellose depending on regional market requirements. Content uniformity is tested according to USP <905>; a 10-capsule sample must produce an acceptance value of ≤ 15.0. Disintegration is performed according to USP <701> in 900 mL purified water at 37°C ± 2°C with discs; the acceptance criterion is complete disintegration within 15 minutes. Dissolution for immediate-release capsule product is conducted in 900 mL of 0.1 N hydrochloric acid at 37°C ± 0.5°C using USP <711> Apparatus II at 50 rpm, with sampling at 15, 30, 45, and 60 minutes; an immediate-release acceptance of Q = 80% at 45 minutes is applied only when the label claims immediate release. Because tobramycin is intended for local luminal exposure rather than systemic absorption when delivered orally, the dissolution test functions as a batch-to-batch product quality indicator rather than a bioequivalence surrogate.

Moisture control is critical because residual water in the blend can plasticize the capsule shell and accelerate degradation of the hygroscopic aminoglycoside sulfate. The encapsulation suite is maintained at 20°C–25°C and relative humidity ≤ 40%; final blend loss on drying is required to be ≤ 2.0% by halogen moisture balance. Capsules are packaged in 45 mL high-density polyethylene bottles with child-resistant caps and 1 g silica gel desiccant canisters; the bottle is induction-sealed. Stability protocols follow ICH Q1A(R2) with storage at 25°C ± 2°C / 60% RH ± 5% RH and 40°C ± 2°C / 75% RH ± 5% RH; assay, related substances, moisture, and microbiological quality are monitored at 0, 3, 6, 9, 12, 18, and 24 months. Published clinical data for oral tobramycin capsules in selective digestive decontamination remain limited compared with neomycin or paromomycin; therefore, the formulation file must include in-use stability and microbiological challenge data when the product is used as a non-absorbed intestinal antibiotic.

Microbiological quality for nonsterile oral capsules is tested per USP <61> and USP <62>. Acceptance criteria are total aerobic microbial count ≤ 10³ CFU/g, total combined yeasts and molds ≤ 10² CFU/g, and absence of Escherichia coli in 1 g. If Salmonella is specified in the regional pharmacopoeia, the absence test is performed on a 10 g composite sample. Batch release for oral capsule product also includes identification by high-performance liquid chromatographic retention time and sulfate ion test, assay of tobramycin activity expressed on the anhydrous, solvent-free basis, and related substances by a validated liquid chromatographic method with charged aerosol detection because tobramycin lacks a strong ultraviolet chromophore.

Why Does Aqueous Granulation of Tobramycin Sulfate Require Binder Viscosity Control Below 250 mPa·s?

High-shear wet granulation of tobramycin sulfate is performed in a top-drive granulator with a 65 L bowl, main impeller speed 150–200 rpm, and chopper speed 1500–3000 rpm. The binder solution is prepared by dispersing hypromellose E5 in purified water at 80°C then cooling to 20°C–25°C to form a 5% w/w solution; viscosity is controlled to 12–18 mPa·s at 20°C with a Brookfield LV viscometer equipped with spindle LV-2 at 60 rpm. If binder viscosity exceeds 250 mPa·s during manufacture, wet mass movement becomes sluggish, wall adhesion increases, and oversized granules appear on the 1.0 mm discharge screen. Purified water is added to the dry blend until wet mass loss on drying reaches 12%–14% w/w; the granulation endpoint is assessed by torque rise and by hand compression. Over-wetting beyond 16% w/w produces a paste that is not recoverable by subsequent drying and requires batch rejection.

Wet mass is discharged through a 4.0 mm square-opening screen into a fluid-bed dryer with inlet air temperature 55°C ± 5°C and product temperature limit 40°C. Drying continues until loss on drying is 1.5%–2.5%; the endpoint is verified by halogen moisture balance at 105°C. The dried granules are milled through a conical mill fitted with a 0.039-inch round-hole screen and square impeller at 1000 rpm. Sieve analysis is performed according to USP <786> using 850 μm, 500 μm, 250 μm, 150 μm, and 75 μm sieves; the target granule D50 is 180–250 μm and fines below 75 μm are limited to ≤ 25%. Granule density is determined by tapped density; a Carr index ≤ 25 and Hausner ratio ≤ 1.25 are required before sachet filling.

Unit dose granules are filled into aluminum foil stick packs using a vertical form-fill-seal machine with auger filling at 20°C–25°C and relative humidity ≤ 35%. Fill weight is verified by an in-line checkweigher with accuracy ± 2 mg; the rejection station removes packs outside ± 5.0% of target. For reconstitution, the granule dose is dispersed in 10 mL of purified water at room temperature; because the formulation does not contain an antimicrobial preservative, the dispersion is single-use and is prepared immediately before administration. Reconstitution time is ≤ 60 seconds with gentle swirling; granule wettability is controlled by the level of colloidal silicon dioxide and by avoiding hydrophobic lubricants in the granule matrix.

Microbiological quality of oral granules follows the same nonsterile limits as capsules: total aerobic microbial count ≤ 10³ CFU/g, total combined yeasts and molds ≤ 10² CFU/g, and absence of Escherichia coli per USP <62>. Packaging integrity of the aluminum foil laminate is tested by vacuum leak detection per ASTM F2338-09; seal strength is measured at 5 N/15 mm minimum using a tensile tester per ASTM F88/F88M-21. Because tobramycin sulfate granules are hygroscopic, the moisture barrier of the laminate must have water vapor transmission rate ≤ 0.5 g/m²/24 h at 38°C and 90% RH. Published data for aqueous granulation of tobramycin sulfate in this specific formulation configuration are limited; the above parameters are derived from general aminoglycoside sulfate processing windows and must be confirmed by process qualification studies.

Tablet Compression of Hygroscopic Tobramycin Sulfate Without Over-Lubrication by Magnesium Stearate

Tablet manufacture from tobramycin sulfate often requires dry granulation because direct compression of the moisture-sensitive powder can be compromised by low bulk density and variation in particle size distribution. Roller compaction is conducted on a 200 mm roll compactor with hydraulic pressure 60–100 bar, roll speed 5–12 rpm, and roll gap 2 mm. Ribbon density is controlled at 1.05–1.15 g/cm³; ribbons are milled through a 1.0 mm rasping screen and classified on an 850 μm sieve to remove fines below 150 μm if the fraction exceeds 30%. The compacted granules are blended with crospovidone and magnesium stearate at 0.5% w/w. Lubrication is limited to 3 minutes in a bin blender at 20 rpm; over-lubrication beyond 10 minutes or at high shear can reduce tablet diametrical tensile strength below 1.0 MPa, producing capping during scale-up.

Compression is carried out on a 45-station rotary press with pre-compression force 2–4 kN and main compression force 8–15 kN, turret speed 30–60 rpm. For a 40 mg tobramycin activity tablet with 300 mg target weight, tablet hardness is 5–8 kp, thickness is measured continuously, and friability is ≤ 1.0% after 100 revolutions according to USP <1216>. Disintegration is performed on 6 tablets in 900 mL purified water at 37°C ± 2°C and must be complete within 15 minutes according to USP <701>. Content uniformity by USP <905> uses 10 tablets with an acceptance value ≤ 15.0; failure has been observed when punch fill depth is allowed to exceed 5 mm due to segregation of fines in the feed hopper.

Film coating is applied with an aqueous Opadry II dispersion to 2.5%–3.0% weight gain in a side-vented pan. Inlet air temperature is 60°C–70°C, product temperature 40°C–45°C, atomizing air pressure 1.5–2.0 bar, and pan speed 2–6 rpm. The coating system is prepared at 10% solids and stirred for 45 minutes before spraying; viscosity is 200–400 mPa·s at 20°C. Coated tablets are dusted and metal-checked; the finished tablet is intended for immediate release, but enteric coating may be applied if distal small intestinal delivery is required for local antimicrobial exposure in the lower gastrointestinal tract. Enteric coating thickness and neutralization resistance are product-specific and must be validated by two-hour acid-stage testing in 0.1 N HCl with ≤ 10% drug release.

Stability of tablet cores is evaluated according to ICH Q1A(R2). Assay by liquid chromatography with charged aerosol detection is used because tobramycin lacks a strong chromophore; related substances are reported against the USP Tobramycin Sulfate Reference Standard. Tablets are packaged in 30-count HDPE bottles with desiccant; closure integrity is tested by induction seal current. A stress stability test for moisture-induced degradation is conducted at 50°C / 75% RH for 1 month; if assay falls below 95.0%, a desiccant quantity adjustment or alternative blister packaging with Aclar laminate is required. The final acceptance criterion for loss on drying of tablets is ≤ 2.5% w/w.

Aseptic processing of tobramycin sulfate injection at nominal concentrations of 10 mg/mL and 40 mg/mL is performed in an ISO 14644-1 Grade 5 filling suite under Grade A unidirectional airflow with velocity 0.36–0.54 m/s as required by EU GMP Annex 1. The solution is compounded in 316L stainless steel vessels with water for injection at 20°C–25°C, starting volume 75%–85% of final batch size, under nitrogen overlay to limit dissolved oxygen. Tobramycin sulfate is added and dissolved with low-shear mixing at 100–150 rpm; sodium chloride is added to achieve osmolality 285–300 mOsm/kg for the 10 mg/mL presentation. The 40 mg/mL concentrate is hyperosmotic and is labeled for dilution before intravenous infusion.

pH adjustment is performed with dilute sulfuric acid to pH 3.5–5.5; in-line pH measurement is verified by potentiometry according to USP <791>. The solution is passed through a 0.45 μm prefilter and then through two 0.22 μm sterilizing-grade polyvinylidene fluoride membrane filters arranged in series. Filter integrity is verified by bubble point before filling and after filling; the acceptable bubble point for a 0.22 μm PVDF filter is taken from the manufacturer’s bacterial retention validation report. Pre-filtration bioburden is sampled and must be ≤ 10 CFU/100 mL. Filling is performed on a rotary piston filling machine into USP Type I borosilicate glass vials; fill volume includes overfill per USP <697> and USP <1151>.

Release testing of the finished injection includes sterility by membrane filtration into soybean-casein digest broth with incubation for 14 days per USP <71> and Ph. Eur. 2.6.1. Bacterial endotoxin is determined by kinetic chromogenic limulus amebocyte lysate with a limit calculated from the maximum labeled dose per USP <85>; the limit is 1.0 EU/mg for a 5 mg/kg maximal bolus dose. Particulate matter is measured by light obscuration per USP <788> Method 1; the acceptance criteria for small-volume parenterals are 6000 particles/container ≥ 10 μm and 600 particles/container ≥ 25 μm. Visible particles are inspected per USP <790>; every inspected vial must be free of visible particulate matter.

Container-closure integrity is validated by vacuum decay per USP <1207>. Headspace oxygen is controlled to ≤ 2.0% by nitrogen flushing before stoppering; residual oxygen is measured by a headspace gas analyzer using a destructive gas probe. The filled vials are stored per ICH Q1A(R2) stability protocols; the photostability guidance ICH Q1B is applied because aminoglycoside solutions can form colored degradation products under light stress. If terminal sterilization is used instead of membrane filtration, a validated autoclave cycle at 121°C for 15 minutes with F0 ≥ 15 minutes is required; however, published data for heat degradation of tobramycin sulfate in aqueous solution at 121°C are limited, so aseptic filtration remains the preferred manufacturing route unless terminal sterilization is specifically validated for the formulation.

When Liquid Injection Is Diluted in 0.9% Sodium Chloride PVC Infusion Bags

Dilution of the 40 mg/mL concentrate into 0.9% sodium chloride injection in polyvinyl chloride bags produces final concentrations between 0.8 mg/mL and 3.2 mg/mL for intravenous infusion over 30–60 minutes. The aseptic transfer is performed under a certified laminar airflow cabinet; a 10 mL Luer-lock syringe and a 19-gauge needle are used to withdraw the concentrate from the rubber-stoppered vial. After injection into the bag, the admixture is mixed by 20 inversions; vigorous shaking is avoided because it introduces air and may accelerate oxidative degradation. The admixture is used within 24 hours at 20°C–25°C or within 72 hours at 2°C–8°C; these limits are consistent with USP <797> low-risk compounded sterile preparations beyond-use dating when prepared under proper aseptic technique.

Aminoglycoside-beta-lactam incompatibility is a critical operational boundary. Tobramycin mixed with a penicillin or cephalosporin in the same infusion container can undergo time- and pH-dependent chemical inactivation; the beta-lactam carbonyl acylates primary amino groups on the deoxystreptamine and aminohexose portions of tobramycin. If co-administration is clinically required, separate infusion lines are used, or the line is flushed with 0.9% sodium chloride between drugs. Published stability data for a specific combination product must be reviewed before any simultaneous infusion; general statements from monographs do not substitute for product-specific compatibility data.

Filtration of the diluted admixture before infusion may be performed through a 0.2 μm low-protein-binding polyethersulfone filter. Cationic tobramycin can bind to negatively charged filter membranes; membrane selection must be justified from the filter manufacturer’s compatibility data. The final admixture pH is typically maintained between 4.0 and 5.5; if the pH is raised above 6.0 by alkaline diluents, precipitation or decreased antimicrobial potency may occur. For infusion pump administration, the PVC bag is protected from direct sunlight because aminoglycoside solutions may form photodegradation products; the line is labeled with the time and date of preparation.

The delivered dose from the intravenous line is influenced by dead volume and sorption to PVC; in-line filter dead space is minimized by priming. Tobramycin is not added to whole blood or amino acid solutions because compatibility data for such admixtures are limited and precipitation or pH-driven degradation cannot be excluded. If fluid restriction requires a higher final concentration, the 40 mg/mL product is diluted only with 0.9% sodium chloride or 5% dextrose injection according to the approved summary of product characteristics; concentration-dependent hyperosmolality is managed by infusion rate control and central venous access when required.

Low Endotoxin API Acceptance Criteria and Elemental Impurity Verification

Incoming tobramycin sulfate API intended for injectable manufacture is released only after the batch certificate includes bacterial endotoxin test data by kinetic turbidimetric or chromogenic limulus amebocyte lysate according to USP <85> or Ph. Eur. 2.6.14. The endotoxin limit is matched to the maximum labeled bolus dose of the finished injection. For a maximum dose of 5 mg/kg tobramycin activity, the limit K/M is 5 EU/kg divided by 5 mg/kg, giving 1.0 EU/mg. To provide process margin, a receiving limit of ≤ 0.5 EU/mg is commonly applied for the API; such a limit is product-specific and must be justified by batch data.

Elemental impurities are controlled according to ICH Q3D. The API supplier must provide validated analytical data for Class 1, Class 2A, Class 2B, and Class 3 elements relevant to the route of synthesis. For parenteral administration, the permitted daily exposure values are lead 5 μg/day, cadmium 2 μg/day, arsenic 15 μg/day, and mercury 3 μg/day. The limit concentration in the finished injection is calculated by dividing the permitted daily exposure by the maximum daily dose of tobramycin. If the projected element concentration is below 30% of the permitted daily exposure, routine batch testing may be omitted; otherwise, each API lot or finished injection lot is tested by inductively coupled plasma mass spectrometry per USP <233>.

Residual solvents in the API are controlled per USP <467>; because tobramycin sulfate is produced by fermentation and semi-synthetic modification, the solvent profile is typically limited to acetone, methanol, or dimethylformamide if a synthetic step is present. The API certificate must state water content, sulfate content, potency on the anhydrous, solvent-free basis, specific optical rotation, pH of a 10% solution, and related substances. Microbial quality of nonsterile API entering oral solid dosage manufacture is tested by USP <61> and USP <62>; total aerobic microbial count ≤ 10³ CFU/g and total combined yeasts and molds ≤ 10² CFU/g are used as release limits, with absence of Escherichia coli and Salmonella in the finished oral dosage form per USP <62>.

Supplier qualification under ICH Q7 and 21 CFR Part 211 is required; the API manufacturing site must be audited for cross-contamination control, water system bioburden, and validated cleaning procedures. Batch-to-batch variance in residual water or sulfate content changes the potency conversion factor; therefore, each API lot is assayed and the formulation weight is adjusted according to the chemical assay. For injectable lines, dedicated or validated shared equipment cleaning is critical because aminoglycosides are potent and can cross-contaminate other parenteral products at low levels; analytical cleaning methods must detect tobramycin in rinse samples at a limit of quantitation no greater than 0.1 μg/mL.